Cadorniga R, Herrero R, Pastoriza P, Molina I T, Gutierrez J A, Iglesias J J
Department of Pharmacy, Faculty of Pharmacy, University of Madrid, Spain.
Eur J Drug Metab Pharmacokinet. 1991;Spec No 3:261-7.
The pharmacokinetics of two oral solid preparations of bezafibrate, available in the Spanish market, was studied. Both preparations were tablets, an immediate-release formulation (A) and the other a slow-formulation (C). We selected a crossover design, and twelve healthy male volunteers participated in the study. Using a sensitive HPLC method, plasma concentrations of bezafibrate were monitored over a period of 12 h. after administration of treatment A and 24 h. for treatment C. In treatment A, two tablets were administered at an interval of six hours. The maximum plasma concentration (Cmax), time to Cmax(tmax) and area under curve (AUC infinity o), in the two doses of treatment A, were compared by analysis of variance and found to be significantly different between the two doses. The relative bioavailability based on (C: 1st-Dose-A) ratio of AUC infinity o was within the range 100 +/- 20%.
对西班牙市场上可得的两种苯扎贝特口服固体制剂的药代动力学进行了研究。两种制剂均为片剂,一种是速释制剂(A),另一种是缓释制剂(C)。我们采用交叉设计,12名健康男性志愿者参与了该研究。使用灵敏的高效液相色谱法,在给予治疗A后的12小时以及治疗C后的24小时内监测苯扎贝特的血浆浓度。在治疗A中,每隔6小时服用两片。通过方差分析比较了治疗A的两剂中的最大血浆浓度(Cmax)、达峰时间(tmax)和曲线下面积(AUC无穷大),发现两剂之间存在显著差异。基于AUC无穷大(C:首剂 - A)比值的相对生物利用度在100±20%范围内。